Neuland Laboratories (NSE:NEULANDLAB) Probability of Financial Distress (%): 0.02% (As of Jun. 26, 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
90 GF Score
Price ₹17,961.00
GF Value ₹16,469.67
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Neuland Laboratories Probability of Financial Distress (%)?

Neuland Laboratories NSE:NEULANDLAB -0.61% 90 Probability of Financial Distress (%) is 0.02% as of Jun. 26, 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,469.67 (Fairly Valued). The stock has 2 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Neuland Laboratories's Probability of Financial Distress (%) is 0.02%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Neuland Laboratories  (NSE:NEULANDLAB) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Neuland Laboratories Probability of Financial Distress (%) Related Terms


NSE:NEULANDLAB vs ZTS: Probability of Financial Distress (%) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuland Laboratories Probability of Financial Distress (%) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's Probability of Financial Distress (%) falls into.


NSE:NEULANDLAB
90GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Probability of Financial Distress (%) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-8.35

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.02%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 0.02% mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Probability of Financial Distress (%) of 0.02% as of Jun. 26, 2026.
Is Neuland Laboratories' Probability of Financial Distress (%) too high?
Neuland Laboratories' current Probability of Financial Distress (%) is 0.02%. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Probability of Financial Distress (%) compare to ZTS?
Neuland Laboratories' Probability of Financial Distress (%) of 0.02% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Drug Manufacturers company?
A good Probability of Financial Distress (%) depends on the Drug Manufacturers industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. Neuland Laboratories's current Probability of Financial Distress (%) is 0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,469.67, compared to a current price of ₹17,961.00 — trading 9.1% above its estimated fair value. The current Probability of Financial Distress (%) is 0.02%. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Probability of Financial Distress (%) is 0.02% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹17,961.00 is trading 9.1% above its estimated GF Value™ of ₹16,469.67. GuruFocus considers Neuland Laboratories to be Fairly Valued.

Key valuation signals for NSE:NEULANDLAB:

  • Probability of Financial Distress (%): 0.02%
  • GF Value™: ₹16,469.67 vs. price of ₹17,961.00 (9.1% above fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score

Get the complete analysis for NSE:NEULANDLAB

Probability of Financial Distress (%) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹17,961.00
Price
₹16,469.67
GF Value